Pulmologix AB today announced the closing of a series B financing of € 9.6 million to develop a new Oral Non-Steroidal Anti-asthmatic (ONSA) for the treatment of early onset allergic asthma.
Pulmologix AB today announced the closing of a series B financing of € 9.6 million to develop a new Oral Non-Steroidal Anti-asthmatic (ONSA) for the treatment of early onset allergic asthma.